BRIEF

on Monogram Technologies Inc. (NASDAQ:MGRM)

Monogram Technologies Secures Approval for Clinical Trials in India

Stock price chart of MONOGRAM ORTHOPAEDICS INC (EBR:MGRM) showing fluctuations.

Monogram Technologies Inc., an AI-driven robotics company, has received regulatory permission from India's CDSCO to import and test its mBôs TKA system. This approval marks the start of a 102-patient clinical trial in partnership with Shalby Hospitals, targeting the efficacy of the system for knee replacement surgery. The trial will be spread over multiple centers in India, with patient enrollment to begin soon and surgeries expected within 90 days.

This collaboration represents a significant milestone in orthopedic healthcare, involving the robotic mBôs TKA System paired with Consensus CKS implants. Training and preparations for the trial have been ongoing, with Monogram positioning staff in India to assist. Leaders from Monogram and Reliance Life Sciences emphasize the trial’s potential to advance orthopedic innovation and improve surgical outcomes.

The project's execution aligns with Monogram's dedication to enhancing patient care through pioneering technologies in orthopedic surgery, which could set new standards of care globally.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Monogram Technologies Inc. news